165 related articles for article (PubMed ID: 12008205)
21. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
[TBL] [Abstract][Full Text] [Related]
22. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Fichtner I; Lemm M; Becker M; Berthold F
Anticancer Drugs; 1997 Feb; 8(2):174-81. PubMed ID: 9073313
[TBL] [Abstract][Full Text] [Related]
23. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
Jones AC; Wilson PA; Steel GG
Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
[TBL] [Abstract][Full Text] [Related]
24. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
25. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
[TBL] [Abstract][Full Text] [Related]
26. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin versus cisplatin in solid tumors: an analysis of the literature.
Lokich J; Anderson N
Ann Oncol; 1998 Jan; 9(1):13-21. PubMed ID: 9541678
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy for advanced ovarian cancer. Advanced Ovarian Cancer Trialists Group.
Stewart L;
Cochrane Database Syst Rev; 2000; (2):CD001418. PubMed ID: 10796788
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
31. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
Harrap KR; Jones M; Siracky J; Pollard LA; Kelland LR
Ann Oncol; 1990; 1(1):65-76. PubMed ID: 2078487
[TBL] [Abstract][Full Text] [Related]
32. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
[TBL] [Abstract][Full Text] [Related]
33. [Antitumor activity of cisplatin and carboplatin against human tumor xenografts serially transplanted into nude mice--with special reference to gastric carcinomas].
Shimoyama Y; Kubota T; Inoue S; Kuzuoka M; Ohishi T; Oka S; Kikuyama S; Ishibiki K; Abe O
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2682-7. PubMed ID: 3307633
[TBL] [Abstract][Full Text] [Related]
34. Establishment of human ovarian tumour lines in nude mice and their responses to platinum analogues.
Sawada M; Ozaki M; Mori Y; Taniguchi H; Tateishi R; Wada A
Eur J Cancer Clin Oncol; 1987 Aug; 23(8):1219-23. PubMed ID: 3308485
[No Abstract] [Full Text] [Related]
35. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
36. Clinical effects of amifostine (Ethyol) in patients treated with carboplatin.
Budd GT; Ganapathi R; Bukowski RM; Murthy S
Eur J Cancer; 1996; 32A Suppl 4():S43-5. PubMed ID: 8976822
[TBL] [Abstract][Full Text] [Related]
37. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
38. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
[TBL] [Abstract][Full Text] [Related]
39. Comparative antitumour activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular carcinoma xenografts.
Harstrick A; Casper J; Schmoll HJ
Int J Androl; 1987 Feb; 10(1):139-45. PubMed ID: 3034790
[TBL] [Abstract][Full Text] [Related]
40. Interaction between cisplatin and mesna in mice.
Dorr RT; Lagel K
J Cancer Res Clin Oncol; 1989; 115(6):604-5. PubMed ID: 2514188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
